GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (FRA:2GH) » Definitions » Additional Paid-In Capital

Merus NV (FRA:2GH) Additional Paid-In Capital : €1,068.05 Mil(As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Merus NV Additional Paid-In Capital?


Merus NV's quarterly additional paid-in capital declined from Sep. 2023 (€1,047.43 Mil) to Dec. 2023 (€1,032.59 Mil) but then increased from Dec. 2023 (€1,032.59 Mil) to Mar. 2024 (€1,068.05 Mil).

Merus NV's annual additional paid-in capital increased from Dec. 2021 (€697.26 Mil) to Dec. 2022 (€822.11 Mil) and increased from Dec. 2022 (€822.11 Mil) to Dec. 2023 (€1,032.59 Mil).


Merus NV Additional Paid-In Capital Historical Data

The historical data trend for Merus NV's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Additional Paid-In Capital Chart

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 397.26 402.86 697.26 822.11 1,032.59

Merus NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 818.97 875.85 1,047.43 1,032.59 1,068.05

Merus NV Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Merus NV Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Merus NV's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV (FRA:2GH) Business Description

Industry
Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV (FRA:2GH) Headlines

No Headlines